ARTreat

ARTreat targets at providing a patient-specific computational model of the cardiovascular system, used to improve the quality of prediction for the atherosclerosis progression and propagation into life-threatening events that need to be treated accordingly.

ARTreat will provide a three-level patient model describing the 3d arterial tree anatomy, the patient-specific blood flow and blood particle dynamics and the biological processes that lead to the creation and progression of atherosclerotic plaques.

ARTreat will apply the developed patient-specific model on two main applications: the clinical decision support and the training. ARTreat will produce two decision support tools to assist clinical cardiologists into providing personalized treatment selection and real-time, on- the-fly advice during invasive interventions, such stent positioning. The aim is to minimize future therapy costs, by providing higher than even possible personalized treatment support. The same patient-specific model will also be used to develop a real-case simulator training, which will support realistic hands-on skill development training to clinical cardiologists.

Finally, ARTreat is coupled with advanced clinical support tools for plaque characterization, and the discovery of new knowledge; associations among heterogeneous data, that can improve the predictive power of the patient-model. It thus supports the medical expert into programming the accumulated knowledge into the existing model and generating an adaptive patient-specific computational tool. Key market players AGFA and SORIN will exploit the ARTreat applications to provide new sophisticated solutions to their product range, while all academic and IT company partners will accumulate significant experience on the new generation patient-specific healthcare services.

For further information, please visit:
http://www.artreat.org

Project co-ordinator:
SWORD TECHNOLOGIES SA

Partners:

  • UNIVERZITET U KRAGUJEVCU
  • COMPUTER SHARING BUCURESTI SRL
  • TECHNOLOGICA EOOD
  • SAS SOFTWARE LIMITED
  • LANZA & THOMPSON INFORMATION TECHNOLOGY SRL
  • TECMIC-TECNOLOGIAS DE MICROELECTRONICA SA
  • FOUNDATION FOR RESEARCH AND TECHNOLOGY HELLAS
  • THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE
  • ADVANCED SIMULATION AND DESIGN GMBH
  • UNIVERSITE PARIS DESCARTES
  • INTERCON SP. Z O.O.
  • EURO (PMS) LIMITED
  • SORIN BIOMEDICA CARDIO S.R.L.
  • AGFA HEALTHCARE N.V.
  • WORLD MATCH LIMITED
  • D.D. SYNERGY HELLAS ANONYMI EMPORIKI ETAIREIA PAROCHIS YPIRESION PLIROFORIKIS
  • CONSIGLIO NAZIONALE DELLE RICERCHE
  • UNIVERSITA DEGLI STUDI DI PARMA

Timetable: from 09/2008 –to 08/2011

Total cost: 10.520.000

EC funding: €7.650.000

Programme Acronym: FP7-ICT

Subprogramme Area: ICT-2007.5.3 Virtual physiological human

Contract type: Collaborative project (generic)

Related news article:

Most Popular Now

The Future of Medicine is Data

At the 2023 Annual J.P. Morgan Healthcare Conference, Owkin Co-founder and CEO Thomas Clozel, MD will outline how data is the future of medicine - from the development of new...

Study Surveys Landscape of Apps Built on…

A study led by Regenstrief Institute Research Scientist Titus K. Schleyer, DMD, PhD, is among the first to survey the current landscape of FHIR® apps, providing a snapshot of how...

New Computer Program 'Learns' to Identif…

Genetic mutations cause hundreds of unsolved and untreatable disorders. Among them, DNA mutations in a small percentage of cells, called mosaic mutations, are extremely difficult to detect because they exist...

Applications Open for SpinLab Accelerato…

The start-up accelerator supports entrepreneurial and innovative teams that want to grow sustainably and successfully scale their business model. With a strong hands-on mentality and a lot of passion, the...

Bayer to Accelerate Drug Discovery with …

Bayer AG and Google Cloud today announced a collaboration to drive early drug discovery that will apply Google Cloud's Tensor Processing Units (TPUs), which are custom-developed accelerators designed to run...

Allscripts Announces Corporate Name Chan…

Allscripts Healthcare Solutions, Inc. announced that, effective January 1, 2023, it has changed its name to Veradigm Inc. (NASDAQ: MDRX). Allscripts had been transitioning its solutions to the Veradigm brand...

220M€ Investment in Testing and Experime…

To make the EU the place where AI excellence thrives from the lab to the market, the European Union is setting up world-class Testing and Experimentation Facilities (TEFs) for AI. Together...

AI Tool Developed to Predict Risk of Lun…

Lung cancer is the leading cause of cancer death in the United States and around the world. Low-dose chest computed tomography (LDCT) is recommended to screen people between 50 and...

Artificial Nerve Cells - Almost Like Bio…

Researchers at Linköping University (LiU), Sweden, have created an artificial organic neuron that closely mimics the characteristics of biological nerve cells. This artificial neuron can stimulate natural nerves, making it...

Bayer Acquires Blackford Analysis Ltd. B…

Bayer announced the acquisition of the global strategic imaging AI platform and solutions provider Blackford Analysis Ltd. The acquisition is part of Bayer's strategy to drive innovation in radiology, including...

For Shared Decision-Making, Telemedicine…

Telemedicine may be just as effective as in-person visits when it comes to shared decision-making and communication for patients undergoing a first-time surgery consultation, according to a study published as...

Veradigm Announces Strategic Investment …

Veradigm Inc. (NASDAQ: MDRX), formerly Allscripts Healthcare Solutions, Inc., announced an investment in Holmusk, a global behavioral health real-world evidence and data analytics company, as part of Holmusk's $45 million...